Work

Prenatal Magnesium Sulfate Exposure Is Not Associated with Different Neurodevelopmental Outcomes by Sex in Extremely Preterm Infants

Year: 2025

Type: article

Abstract: Background/Objectives: Magnesium sulfate (MgSO4) has historically been used in obstetrics as a tocolytic and to prevent eclamptic seizures. MgSO4 has also been investigated as a potential neonatal neuroprotectant for infants born preterm. However, randomized controlled trials of prenatal MgSO4 have shown mixed results, with single-center observational studies also suggesting differential effects by sex. We sought to evaluate sex-dependent associations between prenatal MgSO4 exposure and standardized neurodevelopmental outcomes in a large, multi-center cohort of extremely preterm neonates (24–0/7 to 27–6/7 weeks’ gestation) from the Preterm Erythropoietin Neuroprotection Trial (PENUT). Methods: The relationship between maternal MgSO4 exposure and neurodevelopmental outcomes assessed at 2 years using the Bayley Scales of Infant and Toddler Development Index, 3rd edition was examined by sex in n = 666 infants (n = 328 female, n = 338 male). To account for confounding by indication, we performed both matching and inverse probability weighting using 17 maternal predictors of MgSO4 exposure. Results: In both unadjusted and adjusted (weighted and matched) analyses, no relationship between MgSO4 exposure and neurodevelopmental outcomes was seen, either overall or by sex. Conclusions: This study reaffirms the safety of MgSO4, but appropriate clinical trials of MgSO4 in extremely preterm infants are still required to better understand any effects on neurodevelopmental outcomes.

Source: Brain Sciences

DOI: 10.3390/brainsci15121273